| |
|
|
|
|
|
A group of mucin type glycoprotein Sialosyl Lewis Antigens (SLA),
such as CA19-9 and CA19-5, has come to be recognized as
circulating cancer associated antigens for gastrointestinal cancer.
CA19-9 represents the most important and basic carbohydrate
tumor marker. The immunohistologic distribution of CA19-9 in
tissues is consistent with the quantitative determination of higher
CA19-9 concentrations in cancer than in normal or inflamed tissues.
Recently reports indicates that the serum CA19-9 level is frequently
elevated in the serum of subjects with various gastrointestinal
malignancies, such a
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
Cancer Antigen 125 (CA125) is a surface antigen associated with
epithelial ovarian cancer. In serum, CA125 is associated with a high
molecular weight glycoprotein. Published studies have indicated
that elevated serum CA125 levels can be found in individuals with
serious endometroid, clear-cell and undifferentiated ovarian
carcinoma.
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
The BTA stat Test is an in vitro immunoassay intended for the qualitative detection of bladder tumor antigen in urine of persons diagnosed with bladder cancer. This test is indicated for use as an aid in the management of bladder cancer patients in conjunction with cytology.
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
The UroVysion® Bladder Cancer Kit (UroVysion Kit) is FDA approved and designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from persons with hematuria suspected of having bladder cancer. Results from the UroVysion Kit are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.
|
Company:
Date:
December 10, 2008
|
|
|
|
|
|
|
|
|
|
For the quantitative determination of the Cancer Antigen CA125 concentration in human serum.
|
Company:
Date:
March 03, 2009
|
|
|
|
|